Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Lupe Guerra

Physician Assistant Lutz, FL Physician Assistant

NPI 1205319019 CMS profile 10691615

2971 Pearson James Pl, Lutz, FL 33559

Open in the dashboard

General payments

$15,712

727 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lupe Guerra of Lutz, FL is reported in the CMS Open Payments database as having received $15,712 across 727 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,523 250
2024 General $3,928 180
2023 General $4,663 239
2022 General $1,598 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lupe Guerra
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Lupe Guerra were reported at $5,523. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Lupe Guerra Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $1,598 $155 $48–$522 $149
2023 $4,663 $167 $52–$557 $160
2024 $3,928 $178 $55–$600 $164
2025 $5,523 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. UCB, Inc. $1,319 45 payments
  2. Neurocrine Biosciences, Inc. $1,015 55 payments
  3. ACADIA Pharmaceuticals Inc $847 31 payments
  4. Pfizer Inc. $837 53 payments
  5. AbbVie, Inc. $835 38 payments
  6. US WorldMeds, LLC $833 42 payments
  7. EMD Serono, Inc. $737 21 payments
  8. Teva Pharmaceuticals USA, Inc. $710 33 payments
  9. Argenx US, Inc. $686 41 payments
  10. SK Life Science, Inc. $604 18 payments
  11. Other $7,288 350 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $15,636 720 payments
  2. Education $75 7 payments
Products named General payments · program years 2022–2025
  1. INGREZZA $1,015 55 payments
  2. NUPLAZID $847 31 payments
  3. NURTEC ODT $827 52 payments
  4. ZAVZPRET $703 45 payments
  5. QULIPTA $667 30 payments
  6. Briviact $663 22 payments
  7. Austedo XR $529 27 payments
  8. Gocovri $523 24 payments
  9. Hizentra $516 20 payments
  10. Rystiggo $497 16 payments
  11. Other $9,798 480 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 76 drugs

Part D claims

3,988

Median for Physician Assistant: 241

Drug cost

$3,320,008

Median for Physician Assistant: $4,110

Branded share of claims

37.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 119 $1,126,557
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 22 $618,974
Nuplazid Pimavanserin Tartrate Brand 47 $229,168
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 16 $200,302
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 20 $164,359
Qulipta Atogepant Brand 117 $143,479
Nurtec Odt Rimegepant Sulfate Brand 64 $125,396
Ingrezza Valbenazine Tosylate Brand 13 $104,640
Austedo Deutetrabenazine Brand 14 $91,435
Aimovig Autoinjector Erenumab-Aooe Brand 90 $83,422

The 10 drugs with the highest cost, of 76 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 42 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Gocovri
$445 — —
Rystiggo
$223 — —
INGREZZA
$197 13 —
QULIPTA
$173 117 —
VYVGART Hytrulo
$168 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 42 with Patron

Records

727 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record